| 9.91 -0.17 (-1.69%) | 10-29 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 12.09  |
1-year : | 14.12 |
| Resists | First : | 10.35 |
Second : | 12.09 |
| Pivot price | 9.09 |
|||
| Supports | First : | 7.84 |
Second : | 6.3 |
| MAs | MA(5) : | 9.61 |
MA(20) : | 8.62 |
| MA(100) : | 5.5 |
MA(250) : | 5.06 |
|
| MACD | MACD : | 0.9 |
Signal : | 0.9 |
| %K %D | K(14,3) : | 87.7 |
D(3) : | 84.7 |
| RSI | RSI(14): 71.9 |
|||
| 52-week | High : | 11.72 | Low : | 1.45 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ LXEO ] has closed below upper band by 16.7%. Bollinger Bands are 53.6% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 23 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 10.36 - 10.41 | 10.41 - 10.45 |
| Low: | 9.56 - 9.62 | 9.62 - 9.66 |
| Close: | 9.82 - 9.92 | 9.92 - 9.98 |
Lexeo Therapeutics, Inc. operates as a clinical-stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of HCM caused by TNNI3 mutations. It also develops LX1001, an AAVrh10-based gene therapy candidate for the treatment of APOE4 homozygous; LX1020, a gene therapy candidate for the treatment of APOE4 homozygous; LX1021 for the treatment of APOE4 homozygotes; and LX1004 for the treatment of CLN2 Batten disease. The company was incorporated in 2017 and is based in New York, New York.
Mon, 20 Oct 2025
Lexeo Therapeutics Completes $153.8 Million Public Offering and Private Placement for Cardiovascular Disease Treatments - Quiver Quantitative
Mon, 20 Oct 2025
Lexeo (Nasdaq: LXEO) raises $153.8M; offering closes with private placement - Stock Titan
Sat, 18 Oct 2025
Otero, Lexeo Therapeutics CTO, sells $18,912 in LXEO stock By Investing.com - Investing.com South Africa
Fri, 17 Oct 2025
Robertson, Lexeo Therapeutics CLO, sells $31,529 in LXEO stock By Investing.com - Investing.com Australia
Fri, 17 Oct 2025
Robertson, Lexeo Therapeutics CLO, sells $31,529 in LXEO stock By Investing.com - Investing.com South Africa
Thu, 16 Oct 2025
$135M Financing: Lexeo Therapeutics prices public offering and sells 1.25M pre-funded warrants; close Oct 20, 2025 - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 72 (M) |
| Shares Float | 29 (M) |
| Held by Insiders | 0.4 (%) |
| Held by Institutions | 69.4 (%) |
| Shares Short | 7,320 (K) |
| Shares Short P.Month | 5,890 (K) |
| EPS | -3.22 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 2.55 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -42 % |
| Return on Equity (ttm) | -75.4 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | -1.03 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -1.71 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -95 (M) |
| Levered Free Cash Flow | -54 (M) |
| PE Ratio | -3.09 |
| PEG Ratio | 0 |
| Price to Book value | 3.87 |
| Price to Sales | 0 |
| Price to Cash Flow | -7.51 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|